INTRODUCTION AND OBJECTIVES: Abiraterone acetate (AA/ P) and enzalutamide (ENZ) represent the treatment of choice in men with asymptomatic or mildly symptomatic mCRPC. Altough serial PSA measurements are required to monitor response and progression, the role of serial imaging studies is unclear in daily routine. It was the purpose of our study to evaluate the potential additional benefit of imaging to monitor the disease.
METHODS: A total of 56 patients with mCRPC underwent systemic first line treatment with ENZ or AA/P after failing primary LHRH-therapy. Mean serum testosterone was 34.4 (18 e 48) ng/dl. Patients underwent analysis of the serum markers PSA, alk. Phosphatase, CRP, hemoglobine, and LDH at 3-months intervals. In addition imaging studies were repeated at 3-months intervals or in case of PSA or symptomatic progression.
RESULTS: Mean duration of AA/P treatment is 12.7 (2-19) months and mean duration of ENZ therapy is 17.2 (3-29) months. A PSA-response was achieved in 76% and 81% in the AA/P and the ENZ group, respectively. Beside PSA, responding patients in the AA/P group demonstrated a significant decrease in serum concentrations of LDH (367,96 225,4U/l) and alk. Phosphatase (249,59 117U/l) whereas responding pts in the ENZ group demonstrated a decrease in LDH only (339,5 228,33U/l). Median duration of PSA response is 10.8 and 11.5 months in the AA/P and the ENZ group, respectively. Despite stable serum levels of 0.6 (0.2-0.9) ng/ml and an asymptomatic status, 8 patients exhibited a significant radiographic progression in number and size of lymph node metastases (n¼5) or skeletal metastases (n¼3). 4 pts underwent local therapy of the progressing site by stereotactic radiation and in 4 pts treatment was switched to docetaxel.
CONCLUSIONS: Despite considerable and stable PSAresponse 15% of our patients exhibited significant metastatic progression which would not have been detected without serial imaging studies. Therefore, we strongly advocate imaging studies even in the presence of stable PSA serum levels.
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PD24-05 IMPACT OF ABIRATERONE ACETATE IN THE POST-DOCETAXEL SETTING ON THE SURVIVAL OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS: A POPULATION-BASED STUDY IN QUEBEC
Alice Dragomir*, Joice Rocha, Marie Vanhuyse, Fabio Cury, Jason Hu, Noémie Prévost, Armen Aprikian, Montreal, Canada INTRODUCTION AND OBJECTIVES: Abiraterone was introduced in Quebec in 2012 for metastatic castration-resistant prostate cancer (mCRPC) in the post-docetaxel setting. This study described abiraterone utilization in the early post-approval period and its clinical effectiveness in Quebec, for both post-chemotherapy patients and patients unfit for chemotherapy.
METHODS: A retrospective cohort study was conducted using Quebec public healthcare administrative databases. The study population consisted of men 40 years and older with a diagnosis of prostate cancer (PCa), and who received androgen-deprivation therapy (ADT) (orchiectomy or luteinizing hormone-releasing hormone analogs or antagonists (LHRHa)) between January 2001 and July 2013. In addition, patients should have received a first treatment of abiraterone between 2012 and 2013. Treatment groups were defined as: 1) Abiraterone post chemotherapy and 2) Abiraterone "exception patient", for chemotherapy-ineligible patients treated with abiraterone authorized by the "exception patient" measure category. Study outcomes included overall survival since abiraterone initiation, abiraterone duration, and hospitalization days. Cox proportional hazard regression was used to estimate the effectiveness of abiraterone in the post-docetaxel setting adjusted for several covariates.
RESULTS: Our cohort consisted of 303 mCRPC patients treated with abiraterone (abiraterone post-chemotherapy: 99 and abiraterone "exception patient": 204). The median age was 75.0 for the abiraterone post-chemotherapy group and 80.0 for the abiraterone "exception patient" group. The corresponding median survivals were 12 and 14 months, respectively (log-rank test p-value¼0.815). Risk of death was similar in the abiraterone post-chemotherapy and abiraterone "exception patient" groups (hazard ratio (HR): 0.89; 95%CI 0.57-1.38).
CONCLUSIONS: Effectiveness of abiraterone in older patients who were chemotherapy ineligible was similar to that of patients with prior docetaxel exposure. Overall, real-world survival benefits of abiraterone were similar to the results of the COU-AA-301 trial. 
